Milestone Scientific Provides Major Commercial Growth Update as CompuFlo® Expands Across 30 Million+ Annual Global Epidural Procedures

Company Reports 500+ U.S. Leads, Expanding Healthcare Network Relationships, Federal Market Access, International Distribution and 300+ Issued and Pending Patents Worldwide

ROSELAND, N.J., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE American: MLSS), a medical technology company specializing in advanced computerized injection and drug-delivery technologies, today provided a comprehensive commercial update highlighting significant progress in expanding its CompuFlo® Epidural System across U.S. and international markets.

Milestone believes its proprietary Dynamic Pressure Sensing® technology addresses a substantial opportunity within an estimated 30 million-plus annual epidural procedures globally, including more than 11 million in the United States.

At just 2% penetration of the estimated U.S. procedure market, approximately 220,000 annual procedures would represent $33 million in potential annual disposable revenue, assuming a $150 selling price per procedure. This illustrative opportunity excludes equipment sales, international markets and potential future medical applications. It is not a revenue projection and assumes clinical eligibility, physician adoption and disposable purchasing.

With an expanded commercial organization, growing physician pipeline, established reimbursement pathways, international distribution and a substantial global patent portfolio, Milestone believes it is positioned to pursue a significantly larger share of this market.

• 200%+ Medical Revenue Growth: Medical segment revenue increased 200%+ year-over-year in the second quarter of 2026, demonstrating early commercial momentum.

• 500+ U.S. Commercial Leads: Expanding physician and institutional pipeline generated through targeted sales, digital marketing, medical conferences, physician referrals and clinical outreach.

• Digital Marketing Momentum: Since launching its social media marketing in April 2026, CompuFlo® social media content has generated more than 217,000 views and approximately 1,600 link clicks through October 27, 2026, expanding awareness among potential customers and supporting physician outreach and lead generation.

• Major Healthcare Network Opportunities: Milestone’s development relationship with Pain and Spine Specialists, led by Dr. Sudhir Rao, spans 22 locations across four states. Additional commercial engagement includes Rothman Orthopaedics, Main Line Health and Memorial Health, representing prospective institutional opportunities at varying stages.

• Growing Physician Adoption: The CompuFlo Advisor Program has generated more than 200 procedure-feedback submissions across approximately 15 sites, supporting clinical experience, physician advocacy and reimbursement development.

• Established Medicare Payment Pathways: Approximately $325 per qualifying CPT® 0777T procedure has been reported in Novitas and First Coast jurisdictions, with Avania Medical LLC supporting broader reimbursement and market-access initiatives.

• Expanded U.S. Commercial Organization: Five dedicated medical sales professionals, approximately 15 sales consultants, three distribution partners, and additional clinical, reimbursement and physician-advisor resources support market penetration.

• Federal Healthcare Expansion: Strategic distribution partner Red One Medical provides access to VA, Department of Defense, Defense Health Agency and other federal healthcare customers, supporting potential nationwide institutional adoption.

• Growing International Footprint: Clinical education initiatives in Italy reached more than 40 physicians from over 10 hospitals, while relationships with Movi S.p.A. in Italy, Avalon Medical in Qatar and Luxxustone Spa in Chile support broader international expansion.

• Extensive Global Intellectual Property: Approximately 305 issued patents, including approximately 121 CompuFlo-related patents, together with regulatory approvals in 30 countries, support the Company's technology platform and potential future applications.

• Expanding Clinical Evidence: CompuFlo has been evaluated or utilized at more than 40 universities, academic medical centers and teaching hospitals worldwide, with additional clinical research and academic collaborations underway.

Milestone believes CompuFlo's commercial opportunity is supported by the scale of the global epidural market and its recurring-use business model.

Each additional active physician and procedure creates potential demand for the Company's proprietary disposable products, providing an opportunity to build predictable purchasing patterns as clinical adoption expands.

The Company's commercial strategy focuses on converting physician interest into active accounts through demonstrations, training, initial procedures, reimbursement support and repeat purchasing.

Milestone believes larger multisite physician practices and healthcare systems provide particularly attractive opportunities, as initial successful adoption may enable expansion across additional physicians and affiliated locations.

Milestone is executing a targeted geographic strategy, initially concentrating commercial resources in Medicare jurisdictions with established payment pathways and expanding into additional regions as physician utilization and reimbursement experience develop.

The Company is increasing its visibility through leading pain and neuromodulation conferences, including ASPN, FSIPP and ISPN, together with physician webinars, hands-on education and engagement with key opinion leaders.

Clinical validation remains a central component of this strategy. A recent 79-patient peer-reviewed University of Texas Medical Branch study associated CompuFlo-guided epidural access during spinal cord stimulator implantation with approximately 91% lower adjusted odds of composite complications compared with conventional loss-of-resistance techniques.

Additional research, including a University of Minnesota evaluation of CathCheck®, is intended to support broader clinical understanding and utilization across appropriate epidural applications.

Milestone also intends to leverage its broad intellectual-property portfolio to explore additional applications of Dynamic Pressure Sensing® technology beyond the current epidural market.

“We believe Milestone is entering an important new phase of commercial growth. We are addressing a large global market with patented technology, growing clinical validation, established reimbursement pathways and a significantly expanded commercial organization.

“The scale of the opportunity is compelling. Just 2% penetration of the estimated U.S. procedure market represents approximately $33 million in potential annual disposable revenue at our illustrative selling-price assumption, before considering international expansion, equipment sales or additional medical applications.

“Our commercial strategy is now focused on converting our growing pipeline of more than 500 U.S. opportunities into active accounts, increasing procedure volumes and expanding successful adoption across larger healthcare networks.

“With growing physician utilization, federal market access, expanding international distribution and a substantial global patent portfolio, we believe the Company has established a stronger foundation for long-term growth.

“Our goal is to scale recurring disposable revenue, replicate successful commercialization across additional markets and continue advancing the clinical and utilization evidence necessary to pursue CPT Category I status, supporting broader adoption of CompuFlo.”

Milestone Scientific Inc. is a technology-focused medical research and development company that patents, designs, and develops innovative injection technologies and instruments for medical and dental applications. Milestone Scientific's computer-controlled systems are designed to make injections precise, efficient and increase the overall patient comfort and safety. Their proprietary DPS Dynamic Pressure Sensing Technology® instruments is the platform to advance the development of next-generation devices, regulating flow rate and monitoring pressure from the tip of the needle, through platform extensions of subcutaneous drug delivery, including local anesthetic. To learn more, view the MLSS brand video or visit milestonescientific.com.

This press release contains forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, expected revenues, timing of regulatory approvals and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions, future business decisions and regulatory developments, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission, including without limitation, Milestone's Annual Report for the year ended December 31, 2025. The forward-looking statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.